Purpose: To determine the role of matrix metalloproteinase 9 (MMP9) in advanced glycation end-products (AGEs) induced damage to blood-retinal barrier (BRB) and the therapeutic effects of minocycline, an MMP inhibitor, against the BRB damages.

Methods: Forty-eight Sprague Dawley rats were randomly assigned to 3 groups (16/group): A control group treated with bovine serum albumin (BSA), an AGE-BSA treated group, and a group treated with minocycline after AGE-BSA treatment. The retinas of all the animals were collected 2 weeks after treatment, and the levels of MMP9 protein and mRNA were detected by Western blotting, immunohistochemistry, and semi-quantitative RT-PCR. The permeability of retinal vessels was bio-assayed using the Evans Blue method. The correlation between the vessel permeability and the MMP9 protein levels was analyzed.

Results: Compared with the BSA control group, the expression of retinal MMP9 mRNA and protein were significantly increased in the AGE-BSA group, and the retinal vascular permeability was also increased in the AGE-BSA group. After the minocycline treatment, the MMP9 expression was decreased sharply and the abnormal vascular permeability was improved. There was a significant correlation between the MMP9 expression and retinal vascular permeability.

Conclusion: MMP9 is involved in the AGE-induced retinal damage of vascular permeability, and the abnormal permeability can be partially reversed by treatment with minocycline.

Download full-text PDF

Source
http://dx.doi.org/10.1080/02713680802450984DOI Listing

Publication Analysis

Top Keywords

vascular permeability
16
retinal vascular
12
mmp9
8
mmp9 involved
8
glycation end-products
8
control group
8
group treated
8
mmp9 protein
8
expression retinal
8
increased age-bsa
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!